Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multinational, randomized, controlled phase II/III clinical trial of IB1000 in patients with Cerebellar Ataxia (CA)

Trial Profile

A multinational, randomized, controlled phase II/III clinical trial of IB1000 in patients with Cerebellar Ataxia (CA)

Completed
Phase of Trial: Phase II/III

Latest Information Update: 26 Nov 2018

At a glance

  • Drugs Acetylleucine (Primary)
  • Indications Cerebellar ataxia
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Nov 2018 New trial record
    • 15 Nov 2018 According to an IntraBio media release, final results from the trial are expected in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top